Omics as Useful Tools in Clinical Practice: Are We There Yet?

摘要

Principles guiding clinician decisions of when torecommend adjuvant therapy continue to evolve,though evidence-based lessons from the last 40 years,such as from the Oxford Overview, must not be for-gotten. In the past, use of adjuvant chemotherapy wasprimarily determined by anatomic prognostic mark-ers of recurrence risk, including tumor size and lymphnode status. To reinforce the value of these measures inguiding the decision to offer adjuvant therapy, the 2010Oxford Overview showed that proportional reductionsin early recurrence, any recurrence, and breast cancermortality with use of adjuvant anthracycline-based andtaxane-based chemotherapy were largely independentof age, nodal status, size, estrogen receptor (ER) status,or differentiation (mostly high or intermediate, with. relatively few cases of low-grade disease).